Depressive and Anxiety Symptoms Among People Living with HIV in Turkey: A Cross-sectional Study

HIV ile Yaşayan İnsanlarda Depresyon ve Anksiyete Semptomları: Kesitsel Bir Çalışma

Objective: This study was undertaken to determine the prevalence of depression and anxiety, to assess sociodemographic and clinical determinants of depression and anxiety symptoms, and to identify factors that impact antiretroviral therapy (ART) adherence in people living with HIV (PLWH).

Methods: The study was conducted at a third-level hospital. Many assessment tools have been used to collect data among PLWH, including the Sociodemographic and Clinical Data Form, Mini-Mental Test, Hospital Anxiety and Depression Scale (HADS), and Center for Epidemiologic Studies Depression Scale (CES-D).

Results: 56% of HIV-positive individuals were diagnosed with depression and 37% with anxiety disorder. Differences in terms of monthly income (HAD-depression scale, \( \chi^2 = 6.037, p=0.028 \)), smoking status (HAD-anxiety scale, \( \chi^2 = 8.104, p=0.009 \)), and substance abuse (both HAD-depression and HAD-anxiety scales; \( \chi^2 = 14.367, p=0.000 \), and \( \chi^2 = 18.641, p<0.001 \), respectively) were found. There were significant associations between anxiety and current smoking [Odds ratio (OR)=5.46, 95% confidence interval (CI): 1.77-16.88; \( p=0.03 \)], as well as between depression and low monthly income [OR=3.77, (95% CI: 1.26-11.26; \( p=0.018 \)], and having a single-status (OR=2.68; 95% CI: 1.05-6.86; \( p=0.04 \)]. Individuals with an HIV positivity duration of less than 3 years, the adherence to therapy was lower (OR=9.71; 95% CI: 1.14-82.99; \( p=0.038 \)).

Conclusion: This is the first study from Turkey using HADS and CES-D scales to assess depressive and anxiety symptoms among PLWH. Significant differences were noted between HAD-D and CES-D scales in terms of a diagnosis of depression. Regression analysis showed associations between current smoking and anxiety, between depression and low income and single-status, and between low ART adherence and HIV positivity duration of less than 3 years. Regular follow-up of HIV-positive individuals, especially in terms of depression diagnoses, is of great importance.

Keywords: HIV, depression, anxiety

Öz

Amaç: Bu çalışmamızda amac HIV ile yaşayan insanlarda depresyon ve anxiety bozukluğu prevalansını tespit etmek, depresyon ve anksiyete belirtilerini etkileyen sosyo-demografik ve klinik değişkenleri belirlemek ve antiretroviral tedaviye (ART) uyuşmum etmenleri saptayabilmektir.
Introduction

Recent estimations suggest that depressive disorder and HIV-positivity will be associated with the highest disease burden by 2030[1]. Depression is the most common neuropsychiatric disorder in PLWH that has a very negative impact on the quality of life of these individuals[2]. The prevalence of depressive disorder has been reported to be 3-fold higher among people living with HIV (PLWH) compared to the general population[3]. The reported prevalence of depression in these subjects varies between 20% and 79%, depending on the population studied, characteristics of control subjects, study period, and diagnostic tools used to identify depression[4].

The link between depression and HIV infection is not straightforward, in which depression may represent a risk factor for HIV infection through augmentation of viral transmission[5] or it may result in HIV infection itself. Development of depression among PLWH is associated with many factors including the presence of HIV in the central nervous system, social stigmatization, difficulties in combatting the disease, adverse effect of anti-retroviral agents, secondary complications, and problems of sexuality[6].

Approximately 16% to 44.4% of PLWH cases have also been reported to suffer from any form of anxiety[7]. Currently, PLWH is not adequately and systematically screened for depression in many countries, adversely affecting the response to treatment, ART use, as well as the quality of life[8]. Identification of PLWH with depression not only improves the quality of life and adherence to ART but reduces mortality and morbidity[9]. Studies showing correlations between depression severity and low CD4+ count and high viral load support these observations[10].

The objectives of our study were to determine the prevalence of depression and anxiety, to assess sociodemographic and clinical determinants of depression and anxiety symptoms, and to identify factors that impact ART adherence in PLWH who have been followed up and treated in a third-level Turkish hospital. The severity of depression was assessed with two tools, i.e. Center for Epidemiologic Studies Depression Scale (CES-D), and HAD, that are commonly used in studies involving PLWH. Also, the prevalence rates determined by these two different tools were compared.

Materials and Methods

Study Design and Panels

This study was conducted with the participation of PLWH treated and followed up in a 3rd level hospital in Turkey. Of the overall 250 patients followed up at the Department of Infectious Diseases, 82 agreed to participate. The research team consisted of a psychiatrist and infectious specialists treating disease. All participants were aged 18 years or older, and provided written informed consent. The study protocol was approved by the Ethics Committee of İzmir Tepecik Education and Training Hospital (decision no: 2019/12-17, date: 25th July 2019).
Sociodemographic and Clinical Data Form, Mini-Mental Test, Hospital Anxiety and Depression Scale (HADS), and CES-D administered to subjects who agreed to participate. Also, data on CD4+ and HIV RNA counts were collected. Patients who completed all surveys and measurement tools were included in the study.

**Study Assessments**

Sociodemographic and Clinic Data Form collects information on the following areas: gender, age, marital status, education level, birthplace, monthly income level, smoking status, alcohol use, substance use, duration of HIV positivity, HIV transmission route, CD4+ T cell count/mm$^3$, viral load copies/mL, anti-retroviral therapy status, duration of antiretroviral treatment, presence/absence of secondary complications due to HIV positivity, previous diagnosis of psychiatric disorders, and history of psychiatric disorders in first-degree relatives.

The HADS is used to determine the risk of anxiety and depression as well as to measure the severity and change in the severity of anxiety and depression in a particular patient. It has two sub-scales, one for depression and one for anxiety. The reliability and validity studies of the Turkish version have been completed. The cutoff values for the anxiety and depression subscales of the Turkish version have been set at 10 and 7 points, respectively. The Cronbach’s alpha value for the 14 items was 0.841.

Also, the validity and reliability studies for the CES-D depression scale have been reported previously. Although the CES-D scale is not recommended to establish a diagnosis of depression, it is commonly used as a screening tool for depressive symptoms. It is a four-point Likert type scale consisting of 20 items. The total score ranges between 0 and 60, with different cutoff values for different cultural settings. Based on the US norms, the cutoff value was 16 points. Similarly, a cutoff value of 16 was also adopted for the Turkish version, based on the ROC analysis results in the validity and reliability study. In that study, a good level of internal consistency was found for CES-D, with a Cronbach’s alpha value of 0.889.

**Statistical Analysis**

Study data were entered into the Statistical Package for the Social Sciences 22.0 software. The mean, standard deviation, median, and minimum-maximum were presented for the numerical variables. For categorical variables, frequencies and percentages are presented. Reliability analyses were performed with Cronbach’s alpha coefficients for HADS and CES-D. Cutoff groups for HADS and CES-D were stratified and cross-tables were prepared with independent variables in these groups. The differences in distributions between the groups were compared with chi-square and Fisher’s exact tests. When a p value of less than 0.2 was determined in these tests, a logistic regression analysis was also performed. A backward-stepwise method was used with Wald statistics. The normal distribution of numerical variables was tested. For this purpose, both skewness and kurtosis coefficients and conformity to a normal distribution were evaluated. The association between these variables was examined using non-parametric correlation. For all comparisons, type 1 error was tested at $\alpha=0.05$. The difference between groups was considered significant when the p value was <0.05.

**Results**

**PLWH Demographics and Clinical Characteristics**

Overall, there were 82 participants, 91.4% of whom were male. The mean age was 41.28±12.90 years, with a mean HIV positivity duration of 4.80±3.36 years.

The average scores for the Mini-Mental Test, HAD-depression scale, HAD-anxiety scale, and CES-D were 25.61±3.53, 6.87±4.05, 7.83±4.23, and 22.60±12.60, respectively. Other sociodemographic and clinical data are summarized in Table 1.

**Distribution of Sociodemographic and Clinical Data According to Cutoff of HAD, CES-D and Mini-Mental Test Scores**

Significant differences between the groups were found when the overall study participants were assessed according to HAD-depression cutoff score ($t=-13,757; p<0.000$), HAD-anxiety cutoff score ($t=12,346; p<0.000$), and CES-D cutoff score ($t=13,623; p<0.000$). A significant difference in terms of HAD-depression cutoff score was found between those with or without substance abuse ($\chi^2=6.037, p=0.028$). Current smokers and non-smokers differed significantly concerning HAD-anxiety scale cutoff score ($\chi^2=8.104, p=0.009$). Also, there were significant differences in both HAD-depression ($\chi^2=14.367, p<0.000$) and HAD-anxiety ($\chi^2=18.641, p<0.000$) cutoff scores between those with or without substance abuse. However, the groups did not differ significantly in terms of viral load and CD4+ T helper cell count (Table 2).
Furthermore, when the study group was analyzed on the basis of HAD and CES-D cutoff values for depression, significant differences were found between those diagnosed with depression and those without a diagnosis of depression ($\chi^2=8.511$, $p=0.004$).

Distribution of Sociodemographic and Clinical Data According to ART Adherence

Significant differences in ART adherence were found in those with a HIV positivity history of less than 3 years and those with a HIV positivity history of greater than or equal to 3 years ($\chi^2=6.039$, $p=0.022$). There were no other significant differences with respect to other data (Table 3).

Correlations Between Significant Variables for HIV Infection

Significant correlations were noted between CES-D and HAD-depression ($r=0.423$, $p=0.01$), CES-D and HAD-anxiety ($r=0.621$, $p=0.01$), and HAD-depression and HAD-anxiety scores ($r=0.605$, $p=0.01$). Other correlation data are presented in Table 4.

Logistic Regression Analysis for Sociodemographic and Clinical Data Associated with Depression and Anxiety

A logistic regression analysis was applied to variables with a $p$ value of less than 0.2. Marital status, smoking status, and ART were included in the analysis for HAD-anxiety, that showed a higher burden of anxiety symptoms among smokers [Odds ratio (OR)=5.46; 95% confidence interval (CI): 1.77-16.88, $p=0.03$]. When smoking and monthly income were included in the logistic regression analysis for HAD-depression scores, a monthly income level of <300 USD was associated with increased risk of depression (OR=3.77;
Aşçıbaşı et al. Depressive and Anxiety Symptoms Among People Living with HIV in Turkey

95% CI: 1.26-11.26, p=0.018). Smoking status, marital status, and a HIV positivity history of <3 or greater than or equal to 3 years were subjected to a logistic regression analysis for CES-D. Accordingly, a single-status was associated with an increased occurrence of depression (OR=2.68; 95% CI: 1.05-6.86, p=0.04). For ART adherence, HAD-anxiety and duration of HIV positivity were included in the logistic regression, showing lower adherence to ART in those with a HIV positivity duration of less than 3 years (OR=9.71; 95% CI: 1.14-82.99, p=0.038) (Table 5).

**Table 2. Distribution of sociodemographic and clinical data according to cutoff of HAD, CES-D and Mini-Mental Test scores**

|                        | HAD-depression | HAD-anxiety | CES-D | Minimental Test |
|------------------------|----------------|-------------|-------|-----------------|
|                        | <7             | 7≤          | <10   | 10≤             | <16  | 16≤  | <23 | 23≤ |
| Gender                 |                |             |       |                 |      |      |     |     |
| Male                   | 33 (44%)       | 42 (46%)    | 47 (62.6%) | 28 (37.4%)    | 25 (33.3%) | 50 (66.7%) | 14 (18.6%) | 61 (81.4%) |
| Female                 | 3 (42.6%)      | 4 (57.1%)   | 4 (57.1%) | 3 (42.6%)     | 4 (57.1%) | 3 (42.6%) | 2 (28.5%) | 5 (71.5%) |
| Marital status         |                |             |       |                 |      |      |     |     |
| Married                | 18 (43.9%)     | 23 (56.1%)  | 29 (70.7%) | 12 (29.3%)    | 19 (43.3%) | 22 (53.7%) | 9 (22%)   | 32 (78%)  |
| Single                 | 18 (43.9%)     | 23 (56.1%)  | 22 (53.7) | 19 (46.3%)    | 10 (24.4%) | 31 (75.6%) | 7 (17.1%) | 34 (82.9) |
| Education attainment   |                |             |       |                 |      |      |     |     |
| Primary school         | 18 (37.5%)     | 30 (62.5%)  | 28 (58.3%) | 20 (41.7%)    | 16 (33.3%) | 32 (66.7%) | 10 (20.8%) | 38 (79.2%) |
| High school            | 8 (53.3)       | 7 (46.7%)   | 11 (73.3%) | 4 (26.7%)     | 4 (26.7%) | 11 (73.3%) | 3 (20%)   | 12 (80%)  |
| Bachelor's degree      | 10 (52.6%)     | 9 (47.4%)   | 12 (63.2%) | 7 (36.8%)     | 9 (47.4%) | 10 (52.6%) | 3 (15.8%) | 16 (84.2) |
| Monthly income         |                |             |       |                 |      |      |     |     |
| ≤300 USD               | 23 (36.5%)     | 40 (63.5%)  | 36 (57.1%) | 27 (42.9%)    | 21 (33.3%) | 42 (66.7%) | 12 (19%)  | 51 (81%)  |
| >300 USD               | 13 (68.4%)     | 6 (31.6%)   | 15 (78.9%) | 4 (21.1%)     | 8 (42.1%) | 11 (57.9%) | 4 (21%)   | 15 (79%)  |
| Smoking                |                |             |       |                 |      |      |     |     |
| Yes                    | 18 (36%)       | 32 (64%)    | 25 (50%) | 25 (50%)       | 14 (28%)  | 36 (72%) | 9 (18%)  | 41 (82%)  |
| No                     | 18 (56.3%)     | 14 (43.8)   | 26 (81%) | 6 (19%)        | 15 (46.9%) | 17 (51.3%) | 7 (21.9%) | 25 (78.1%) |
| Alcohol use            |                |             |       |                 |      |      |     |     |
| Yes                    | 20 (48.8%)     | 21 (51.2%)  | 25 (61%) | 16 (39%)      | 14 (34.1%) | 27 (65.9%) | 9 (22%)  | 32 (78%)  |
| No                     | 16 (39%)       | 25 (61%)    | 26 (63.4%) | 15 (36.6%)    | 15 (36.6%) | 26 (63.4%) | 7 (17.1%) | 34 (82.9) |
| Substance abuse        |                |             |       |                 |      |      |     |     |
| Yes                    | 0 (0%)         | 15 (100%)   | 2 (13.3%) | 13 (86.7%)    | 1 (6.7%) | 14 (93.3%) | 2 (13.3%) | 13 (86.7%) |
| No                     | 36 (53.7%)     | 31 (46.3%)  | 49 (73.1%) | 18 (26.9%)    | 28 (41.8%) | 39 (58.2%) | 14 (20.9%) | 53 (79.1%) |
| Secondary complication |                |             |       |                 |      |      |     |     |
| Yes                    | 19 (42.2%)     | 26 (57.8%)  | 28 (62.2%) | 17 (37.8%)    | 17 (37.8%) | 28 (62.2%) | 10 (22.2%) | 35 (77.8%) |
| No                     | 17 (45.9%)     | 20 (54.1%)  | 23 (62.2%) | 14 (37.8%)    | 12 (32.4%) | 25 (67.6%) | 6 (16.2%) | 31 (83.8%) |
| Viral load copy/mL     |                |             |       |                 |      |      |     |     |
| >50                    | 8 (42.1%)      | 11 (57.9%)  | 11 (57.9%) | 8 (42.1%)     | 4 (21.1%) | 15 (78.9) | 3 (15.8%) | 16 (84.2%) |
| <50                    | 28 (44.4%)     | 35 (55.6%)  | 40 (63.5%) | 23 (36.5%)    | 25 (39.7%) | 38 (60.3%) | 13 (20.6%) | 50 (79.4%) |
| CD4+ T helper          |                |             |       |                 |      |      |     |     |
| 200+                   | 34 (43%)       | 45 (57%)    | 48 (60.8%) | 31 (39.2%)    | 28 (35.4%) | 51 (64.6%) | 16 (20.3%) | 63 (79.7%) |
| <200                   | 2 (66.7%)      | 1 (33.3%)   | 3 (100%)  | 0             | 1 (33.3%) | 2 (66.7%) | 0         | 3 (100%)  |

χ² = 6.037, p=0.028; **χ² = 8.104, p=0.009; *χ² = 14.367, p<0.000; **χ² = 18.641, p<0.000.

HAD: Hospital Anxiety and Depression Scale, CES-D: Center for Epidemiologic Studies Depression Scale

Discussion

In this study, the prevalence of depression among PLWH was 56.1% and 64.6% based on HAD-D and CES-D scales, respectively. In a 2011 review by Sherr et al.[11] involving 90 studies, the reported prevalence of depression in
these subjects varied significantly between 11% and 80%, depending on the tools used to identify depression, sample groups, and cutoff values used. In that same review, the prevalence based on CES-D was between 35% and 42.8%.

In another study where a HAD cutoff value of 11 points used to diagnose depression among PLWH, the prevalence of anxiety and depression were 4.8% and 3.1%, respectively (12). However, in another study with a large sample size, where
Aşçıbaşı et al. Depressive and Anxiety Symptoms Among People Living with HIV in Turkey

A cutoff value of 8 was used for HAD, anxiety was found in 27.4% and depression found in 32.9% of the patients. In a systematic global review, the reported prevalence of anxiety and depression in countries with low to middle income were 33.92% and 41.36%, respectively. In this study, the observed prevalence of depression for a CES-D cutoff value of 16 points was 35%, consistent with the above-described observations. However, the prevalence of anxiety and depression based on HAD scores were 62.2% and 43.9%, respectively, which were higher than the previously published figures. We believe that this difference may be accounted for by the HAD cutoff values used in different communities and the variations in sample characteristics. The significant difference in depression prevalence as identified by CES-D and HAD-D may be related to the fact that some of the items of HAD-D may be difficult to comprehend, define serious depression and excludes any items assessing the somatic symptoms, while CES-D has an item that assesses the somatic aspects of the disease.

Table 4. Correlations between significant variables for HIV Infection

| Variables             | 1     | 2     | 3     | 4     | 5     | 6     | 7     |
|-----------------------|-------|-------|-------|-------|-------|-------|-------|
| 1. CES-D              |       |       |       |       |       |       |       |
| 2. HAD-anxiety        | 0.621*|       |       |       |       |       |       |
| 3. HAD-depression     | 0.423*| 0.605**|       |       |       |       |       |
| 4. Mini-Mental Test   | -0.007| -0.006| 0.021 |       |       |       |       |
| 5. CD4+ T helper      | 0.149 | 0.061 | -0.006| -0.129|       |       |       |
| 6. Viral load         | 0.182 | 0.180 | 0.130 | 0.082 | -0.177|       |       |
| 7. HIV+ duration      | -0.169| -0.056| -0.019| -0.106| 0.128 | -0.310**|       |
| 8. Age                | -0.249*| -0.183| -0.105| -0.100| -0.031| -0.074| 0.389**|

*Correlation is significant at the 0.05 level (2-tailed).
**Correlation is significant at the 0.01 level (2-tailed).

HAD: Hospital Anxiety and Depression Scale, CES-D: Center for Epidemiologic Studies Depression Scale

Table 5. Logistic regression analysis for sociodemographic and clinical data associated with depression, anxiety and ART

**HAD-A**

| Variables | B     | S.E.  | Wald  | p      | Exp (B) | 95% CI for exp (B) |
|-----------|-------|-------|-------|--------|---------|---------------------|
| Constant  | -2.130| 0.568 | 14.057| 0.000  | 0.12    |                     |
| Smoking   | 1.698 | 0.576 | 8.689 | 0.003  | 5.46    | 1.77 16.88          |

**HAD-D**

| Variables          | B     | S.E.  | Wald  | p      | Exp (B) | 95% CI for exp (B) |
|--------------------|-------|-------|-------|--------|---------|---------------------|
| Constant           | -0.773| 0.494 | 2.454 | 0.117  | 0.462   |                     |
| Monthly income     | 1.327 | 0.559 | 5.639 | 0.018  | 3.77    | 1.26 11.26          |

**CES-D**

| Variables         | B     | S.E.  | Wald  | p      | Exp (B) | 95% CI for exp (B) |
|-------------------|-------|-------|-------|--------|---------|---------------------|
| Constant          | 0.147 | 0.313 | 0.219 | 0.640  | 1.16    |                     |
| Marital status    | 0.985 | 0.480 | 4.210 | 0.040  | 2.68    | 1.05 6.86           |

**ART**

| Variables         | B     | S.E.  | Wald  | p      |         | 95% CI for exp (B) |
|-------------------|-------|-------|-------|--------|---------|---------------------|
| Constant          | -3.761| 1.012 | 13.825| 0.000  | 0.023   |                     |
| HIV+duration      | 2.273 | 1.095 | 4.312 | 0.038  | 9.71    | 1.14 82.99          |

HAD: Hospital Anxiety and Depression Scale, CES-D: Center for Epidemiologic Studies Depression Scale, ART: Antiretroviral therapy, CI: Confidence interval
There were significant differences in HAD scores between current smokers and non-smokers as well as between drug users and non-users. Compared to HIV-negative individuals, PLWH has been reported to have a higher prevalence of alcohol and drug use\textsuperscript{(26)}.

In a study by Shuter et al.\textsuperscript{(27)}, depression, and anxiety were reported in 73.3% and 67.3% of the smoker PLWH, respectively; in that study, most participants reported cigarette use for tackling anxiety and depression.

A high incidence of substance/drug use has been reported among PLWH. In a study, approximately 50% of PLWH have been reported to be active drug users\textsuperscript{(28)}. Drug use is associated with adverse effects among PLWH due to many reasons. For instance, HIV transmission may occur directly via injectable substances and indirectly via non-injectable substances due to risky sexual behavior\textsuperscript{(29)}. Furthermore, drug use may reduce the adherence to ART and may lead to disease progression\textsuperscript{(19)}. Additionally, drug use has negative impacts on the response to therapy\textsuperscript{(19)}. An association between depression and substance use has been reported for PLWH\textsuperscript{(19)}. It has been proposed that the main motivation behind substance use in these individuals may be related to the need to avoid negative mood or stress. Therefore, interventions directed at substance use among PLWH carry major clinical significance.

It has been well established that among PLWH, adherence to ART is the second most important factor for disease progression and death after CD4+ count. In our study, ART adherence was significantly different among those with a HIV positivity history of less than 3 years and greater than or equal to 3 years. These observations were also confirmed in our logistic regression analysis, similar to some other previous studies\textsuperscript{(22)}. It is possible that patients with a HIV positivity duration of more than 3 years may have more acceptance and insights of their condition. However, when individuals with HIV positivity of <3 or greater than or equal to 3 years compared concerning cut off points for depression and anxiety, no significant correlations were found, which may indicate that depression and anxiety do not present an obstacle for the continuation of ART. Also, the negative correlation between HIV positivity duration and the viral load supports this observation. As shown in the table, no effect of other sociodemographic and clinical variables on ART use was found.

Significant correlations were identified between tools used to evaluate depression and anxiety, which is an important finding in terms of the consistency of our study findings. Studies assessing the mental health in PLWH in Turkey are scarce in number, and none of the previous studies used CES-D and HADS. Therefore, our study has shown that these two tools may be used to assess depression and anxiety in Turkish PLWH.

As expected, a significant correlation between the duration of HIV positivity and age was observed. Effective ART known to prolong lifespan in PLWH. Even in patients advancing into AIDS, the reported 10-year survival rate with HAART is 61\%\textsuperscript{(28)}.

As shown by our regression analysis, an association between smoking and increased HAD-anxiety scores was present, with PLWH having a 3-fold increased prevalence of smoking\textsuperscript{(24)}. One possible explanation for the anxiety symptoms in these subjects involves the disruption of the biological stress pathways (e.g., hypothalamic-pituitary-adrenal axis and sympathetic-adrenal-medullary axis) by HIV\textsuperscript{(29)}. Similarly, HIV/AIDS may be related to behavioral practices such as smoking, substance use, and alcohol use that may aggravate or cause persistence of anxiety symptoms\textsuperscript{(24)}. In fact, based on a heuristic integrative model, a mutual relationship exists between smoking and anxiety\textsuperscript{(16)}. This explains the multitude of interventions aimed at the cessation of smoking among PLWH, along with relevant studies.

There was a statistically significant difference in HAD-D scores in subjects with a monthly income level of <300 USD and ≥300 USD. The association between low income level and HAD-D score was also maintained in the logistic regression analysis. In another study where Beck Depression Inventory was used, similar associations between low income and increased severity of depression were reported among PLWH\textsuperscript{(27)}. Conversely, no such relationships could be observed in another study, using the same measurement tool\textsuperscript{(28)}. It appears that the cutoff value used for defining low-income level may have a significant impact on the association between depression and income level. Again, in a comprehensive meta-analysis, depressive PHWL were more likely to have low adherence to ART compared to those without depression\textsuperscript{(29)}. It may be assumed that low income level may predispose the individuals to depression, with a consequent decrease in ART adherence.

An association between single-status and CES-D scores was found in our group of PLWH. Several previous studies also reported links between single-status and increased depression severity\textsuperscript{(20)}. Similarly, 13-fold increased mortality
was reported among single PLWH compared to married PLWH (marital status and HIV/AIDS mortality: evidence from the US National Longitudinal Mortality Study). These data suggest that social support is an important determinant of the mental health among PLWH, and may even have a protective role against depression.

**Study Limitations**

The limitations of the study include the selection of the sample group from a single center and most it being male.

**Conclusion**

This is the first study in Turkey where HAD and CES-D scales were used to assess depression and anxiety among PLWH. Significant differences in terms of the diagnostic yield of HAD-D and CES-D scales were observed. Significant differences in the occurrence of depression and anxiety were found based on smoking and substance use status, while monthly income level had a significant impact on depression incidence. However, CD4+ count and viral load did not appear to affect the results. Also, an HIV positivity history of longer than 3 years increased ART adherence. The results of the regression analyses showed associations between anxiety and smoking; between depression and low income level and single-status; and low ART adherence and HIV positivity duration of less than 3 years.

**Ethics**

**Ethics Committee Approval:** The study protocol was approved by the Ethics Committee of İzmir Tepecik Education and Research Hospital (decision no: 2019/12-17, date: 25th July 2019).

**Informed Consent:** Consent form was filled out by all participants.

**Peer-review:** Externally and internally peer-reviewed.

**Authorship Contributions**

Surgical and Medical Practices: K.A., H.A.U., S.A., U.S., Concept: K.A., H.A.U., S.A., U.S., Design: K.A., H.A.U., S.A., U.S., Data Collection or Processing: K.A., H.A.U., S.A., U.S., Analysis or Interpretation: K.A., H.A.U., S.A., U.S., Literature Search: K.A., H.A.U., S.A., U.S., Writing: K.A., H.A.U., S.A., U.S.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

**References**

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
2. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001;58:721-8.
3. Do AN, Rosenberg ES, Sullivan PS, et al. Excess burden of depression among HIV-infected persons receiving medical care in the United States: data from the medical monitoring project and the behavioral risk factor surveillance system. PLoS One 2014;9:e92842.
4. Bhatia R, Hartman C, Kallen MA, Graham J, Giordano TP. Persons newly diagnosed with HIV infection are at high risk for depression and poor linkage to care: results from the Steps Study. AIDS Behav 2011;15:1161-70.
5. Meade CS, Sikkema KJ. HIV risk behavior among adults with severe mental illness: a systematic review. Clin Psychol Rev 2005;25:433-57.
6. Schustor R, Boronovatov M, Hunt E. The influence of depression on the progression of HIV: direct and indirect effects. Behav Modif 2012;36:123-45.
7. Ingersoll K. The impact of psychiatric symptoms, drug use, and medication regimen on non-adherence to HIV treatment. AIDS Care 2004;16:199-211.
8. Carrico AW, Bangsberg DR, Weiser SD, Chartier M, Dilworth SE, Riley ED. Psychiatric correlates of HAART utilization and viral load among HIV-positive impoverished persons. AIDS 2011;25:1113-8.
9. Coleman SM, Blashill AJ, Gandhi RT, Safren SA, Freudenreich O. Impact of integrated and measurement-based depression care: clinical experience in an HIV clinic. Psychosomatics 2012;53:51-7.
10. Alciati A, Gallo L, Monforte AD, Brambilla F, Mellado C. Major depression-related immunological changes and combination antiretroviral therapy in HIV-seropositive patients. Hum Psychopharmacol 2007;22:33-40.
11. Sherr L, Clucas C, Harding R, Sibley E, Catalan J. HIV and depression—a systematic review of interventions. Psychol Health Med 2011;16:493-527.
12. Prasithsirikul W, Chongthawonsatid S, Ohata PJ, et al. Depression and anxiety were low amongst virally suppressed, long-term treated HIV-infected individuals enrolled in a public sector antiretroviral program in Thailand. AIDS Care 2017;29:299-305.
13. Yang Z, Huang X, Liu X, et al. Psychometric Properties and Factor Structure of the Chinese Version of the Hospital Anxiety and Depression Scale in People Living With HIV. Front Psychiatry 2019;10:346.
14. Lowther K, Selman L, Harding R, Higginson IR. Experience of persistent psychological symptoms and perceived stigma among people with HIV on antiretroviral therapy (ART): a systematic review of interventions. Psychol Health Med 2011;16:493-527.
15. Ayis SA, Ayerbe L, Ashworth M, DA Wolfe C. Evaluation of the hospital anxiety and depression scale (HADS) in screening stroke patients for symptoms: item response theory (IRT) analysis. J Affect Disord 2018;228:33-40.
16. Pence BW, Miller WC, Whetten K, Eron JJ, Gaynes BN. Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States. J Acquir Immune Defic Syndr 2006;42:298-306.
17. Shutter J, Bernstein SL, Moadel AB. Cigarette smoking behaviors and beliefs in persons living with HIV/AIDS. Am J Health Behav 2012;36:75-85.
18. Benotsch EG, Martin AM, Koester S, Cejka A, Luckmann D. Nonmedical use of prescription drugs and HIV risk behavior in gay and bisexual men. Sex Transm Dis 2011;38:105-10.
19. Doshi RK, Vogenthaler NS, Lewis S, Rodriguez A, Metsch L, del Rio C. Correlates of antiretroviral utilization among hospitalized HIV-infected crack cocaine users. AIDS Res Hum Retroviruses 2012;28:1007-14.

20. Henrich TJ, Lauder N, Desai MM, Sofair AN. Association of alcohol abuse and injection drug use with immunologic and virologic responses to HAART in HIV-positive patients from urban community health clinics. J Community Health 2008;33:69-77.

21. Hampton MC, Halkitis PN, Mattis JS. Coping, drug use, and religiosity/spirituality in relation to HIV serostatus among gay and bisexual men. AIDS Educ Prev 2010;22:417-29.

22. Neupane S, Dhungana GP, Ghimire HC. Adherence to antiretroviral treatment and associated factors among people living with HIV and AIDS in CHITWAN, Nepal. BMC Public Health 2019;19:720.

23. Poorolajal J, Hooshmand E, Mahjub H, Esmailnasab N, Jenabi E. Survival rate of AIDS disease and mortality in HIV-infected patients: a meta-analysis. Public Health 2016;139:3-12.

24. Niaura R, Shadel WG, Morrow K, Tashima K, Flanigan T, Abrams DB. Human immunodeficiency virus infection, AIDS, and smoking cessation: The time is now. Clin Infect Dis 2000;31:808-12.

25. Danese A, Caspi A, Williams B, et al. Biological embedding of stress through inflammation processes in childhood. Mol Psychiatry 2011;16:244-6.

26. Brandt C, Zvolensky MJ, Woods SP, Gonzalez A, Safren SA, O’Cleirigh CM. Anxiety symptoms and disorders among adults living with HIV and AIDS: A critical review and integrative synthesis of the empirical literature. Clin Psychol Rev 2017;51:164-84.

27. Su X, Lau JT, Mak WW, et al. Prevalence and associated factors of depression among people living with HIV in two cities in China. J Affect Disord 2013;149:108-15.

28. Perazzo JD, Currie J, Horvat Davey C, Lambert J, Webel AR. Depression and social capital in people living with HIV. J Psychiatr Ment Health Nurs 2020;27:54-61.

29. Uthman OA, Magidson JF, Safren SA, Nachega JB. Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis. Curr HIV/AIDS Rep 2014;11:291-307.

30. Egbe CO, Dakum PS, Ekong E, Kohrt BA, Minto JG, Ticao CJ. Depression, suicidality, and alcohol use disorder among people living with HIV/AIDS in Nigeria. BMC Public Health 2017;17:542.